p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy

• DOI: 10.1038/s41416-019-0429-2
• Publication Date: 2019-03-21T00:04:09Z
• Authors: Hyeon Jeong Oh; Jeong Mo Bae; Xianyu Wen; Seorin Jung; Younghoon Kim; Kyung Ju Kim; Nam-Yun Cho; Jung Ho Kim; Sae-Won Han; Tae-You Kim; Gyeong Hoon Kang
• Keywords: FOLFOX; Microsatellite Instability

We attempted to elucidate whether p53 expression or TP53 mutation status was associated with cancer-specific survival in adjuvant FOLFOX-treated patients stage III high-risk II colorectal cancer (CRC). analysed CRCs (N = 621) for the presence of alterations and expression, using targeted resequencing immunohistochemistry. were grouped into four subsets according status, which included p53-no, mild, moderate strong expression. The distributions 19.85, 11.05, 17.7% 51.5% groups, respectively. Cases p53-mild group a more frequent proximal location, undifferentiated histology, lower N category, extraglandular mucin production, microsatellite instability, CIMP-P1, CK7 decreased CDX2 compared those cases p53-no p53-strong groups. According analysis, showed poor 5-year relapse-free (hazard ratio (HR): 2.71, 95% confidence interval (CI) 1.60–4.60, P < 0.001) (HR: 2.90, CI 1.28–6.57, 0.011). found be an independent prognostic marker CRC.